Stephen Wong, MD
Allergy · Hacienda Heights, CANPI 1104977008
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,825 of the $49,546 with a category attached, or 90.5%. AstraZeneca accounts for 97.2% of it on its own, with 13 other manufacturers making up the rest. Among allergy clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $286.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$48K
- GSK$351
- AbbVie$200
- Amgen$176
- Sanofi-aventis U.S. LLC$161
- Novartis$159
- plus $339 from 8 others
What the payments were for
- Speaking & faculty fees$44,82590%
- Travel & lodging$2360%
- Food & beverage$4,2839%
- Education$2020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 99 | $48,160 |
| GSK | 30 | $351 |
| AbbVie | 5 | $200 |
| Amgen | 9 | $176 |
| Sanofi-aventis U.S. LLC | 2 | $161 |
| Novartis | 9 | $159 |
| Regeneron Healthcare Solutions, Inc. | 6 | $104 |
| Sanofi | 4 | $89 |
| Optinose US, Inc. | 2 | $34 |
| CSL Behring | 2 | $32 |
| Pfizer | 2 | $29 |
| Jubilant Hollisterstier LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,546 in reported general payments places this provider in the 90th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 54 | $187,333 |
| Fasenra PenBenralizumab | 26 | $145,988 |
| Dupixent PenDupilumab | 37 | $140,377 |
| FasenraBenralizumab | 22 | $127,646 |
| NucalaMepolizumab | 31 | $105,455 |
| Dupixent SyringeDupilumab | 27 | $96,031 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $34,532 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $32,593 |
| Qvar RedihalerBeclomethasone Dipropionate | 60 | $19,619 |
| Spiriva RespimatTiotropium Bromide | 22 | $17,605 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $13,767 |
| Arnuity ElliptaFluticasone Furoate | 30 | $9,703 |
| DuleraMometasone/Formoterol | 18 | $8,310 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $6,020 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $5,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $48,160 | $167,32375 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $351 | $161,517129 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $19,61960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 allergy providers in California.
Other allergy in Hacienda Heights
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Michelle YasharpourBeverly Hills$48K
- Stuart EpsteinBeverly Hills$42K
- Angela SabryFresno$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.